Clinical assessment of m-protein response in multiple myeloma
An anti-idiotypic antibody fused to human albumin addresses interference in IFE for MOR202-treated multiple myeloma patients, ensuring accurate M protein evaluation and adherence to IMWG criteria.
Patent Information
- Application Number
- JP2024157490
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-03-04
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2037-03-03
AI Technical Summary
Current methods for evaluating M protein levels in multiple myeloma patients treated with therapeutic antibodies like MOR202 face interference issues in immunofixation electrophoresis (IFE), making it difficult to accurately assess clinical response according to International Myeloma Working Group (IMWG) criteria.
Development of an anti-idiotypic antibody against MOR202 fused to human albumin, which shifts the antibody in IFE, allowing for clear differentiation between MOR202-related signals and endogenous M protein levels.
The anti-idiotypic antibody-albumin fusion effectively mitigates interference, enabling accurate clinical evaluation of M protein responses and adherence to IMWG criteria by clearly distinguishing between treatment-related and disease-related signals in IFE.
Smart Images

Figure 2024169455000029 
Figure 2024169455000030 
Figure 2024169455000031
Abstract
Description
[Background technology]
[0001] Multiple myeloma (MM) is a blood cancer involving the clonal proliferation of malignant plasma cells. MM is the most common malignant plasma cell neoplasm and the second most common hematologic malignancy in the United States. The age-adjusted incidence in the United States is 5.5 cases per 100,000, and the annual incidence reaches approximately 6 to 7 cases per 100,000 in the United Kingdom.
[0002] Plasma cells produce immunoglobulins (also called gamma globulins), which consist of heavy chains (IgG, IgA, IgM, IgD, or IgE) and light chains (kappa or lambda) that bind together. One plasma cell produces one type of immunoglobulin (e.g., IgA kappa or IgG kappa). Normally, the body contains a variety of different plasma cells ("polyclonal"), so the immunoglobulins in the serum also represent a wide range of different formats and specificities (polyclonal). In the case of multiple myeloma, the malignant cells are only one or a few separate copies of the plasma cell, and the immunoglobulins secreted by the cells are considered to be monoclonal.
[0003] This monoclonal immunoglobulin is called the M protein or paraprotein and may consist of a heavy chain (mostly IgG or IgA, but also IgM, IgD, or IgE) and a light chain (kappa or lambda) or a truncated form of the immunoglobulin. Increased levels of M protein in serum are used to identify B cell malignancies, such as MM.
[0004] Currently, several staging systems are used to diagnose and monitor response in multiple myeloma: a) Durie and Salmon Staging System, (b) International Staging System (ISS) and International Myeloma Working Group (IMWG). The Durie and Salmon staging system includes features that evaluate tumor cell mass, high serum immunoglobulin (Ig)G levels, end-organ damage, and osteolytic bone lesions. The ISS places more emphasis on disease burden based on β2-microglobulin and serum albumin levels. The IMWG considers both molecular and cytogenetic abnormalities, specifically, reduction of M protein over time is one of the most important factors and is used to evaluate disease progression and treatment success.
[0005] Protein expression characteristic of multiple myeloma includes monoclonal (M) protein concentrations (IgG, IgA, IgA, IgD), light chain concentrations (including kappa [κ] and lambda [λ]), abnormal β2-microglobulin, elevated levels of serum albumin, creatinine, and hemoglobin, and the finding of bone marrow plasma cells (5% or more). Measurement of protein (e.g., M protein) expression produced by a patient can be accomplished by a number of methods. Tests to measure M protein include 24-hour urine collection test, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), and serum free light chain (sFLC) assay.
[0006] CD38 is an example of an antigen expressed on malignant plasma cells and other lymphocytes, and therefore represents a therapeutic target in the treatment of multiple myeloma and other gammopathy. Functions attributed to CD38 include receptor mediation in adhesion and signaling events, as well as (ecto)enzymatic activity. As an ectoenzyme, CD38 uses NAD+ as a substrate for the formation of cyclic ADP ribose (cADPR) and ADPR, and of nicotinamide and nicotinic acid adenine dinucleotide phosphate (NAADP). cADPR and NAADP have been shown to function as second messengers for Ca2+ mobilization. By converting NAD+ to cADPR, CD38 regulates extracellular NAD+ concentration and therefore cell survival by regulating NAD-induced cell death (NCID). In addition to signaling via Ca2+, CD38 signaling occurs via crosstalk with antigen receptor complexes on T and B cells, or other types of receptor complexes, such as MHC molecules, and is thus involved in several cellular responses, as well as in IgG switching and secretion.
[0007] Antibodies specific for CD38 are in development for the treatment of multiple myeloma. Antibodies specific for CD38 are described in WO 1999 / 62526 (Mayo Foundation); WO 200206347 (Crucell Holland); U.S. Patent Application Publication No. 2002164788 (Jonathan Ellis) (incorporated by reference in its entirety); WO 2005 / 103083 (MorphoSys AG), U.S. Patent Application No. 10 / 588,568 (incorporated by reference in its entirety), WO 2006 / 125640 (MorphoSys AG), U.S. Patent Application No. 11 / 920,830 (incorporated by reference in its entirety), and WO 2007 / 042309 (MorphoSys No. 12 / 089,806, which is incorporated by reference in its entirety; WO 2006099875 (Genmab), U.S. Ser. No. 11 / 886,932, which is incorporated by reference in its entirety; WO 2011154453A1 (Genmab), U.S. Ser. No. 13 / 702,857, which is incorporated by reference in its entirety; WO 08 / 047242 (Sanofi-Aventis), U.S. Ser. No. 12 / 441,466, which is incorporated by reference in its entirety. No. 13 / 341,860 and U.S. Patent Application No. 13 / 977,207, both of which are incorporated by reference in their entireties, and WO 2014178820A1 (Teva).
[0008] Treatment with anti-CD38 antibodies in MM patients can result in partial or complete clearance of M protein produced by multiple myeloma cells. Both serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) are essential assays used to identify monoclonal proteins and characterize their immunotypes in patients with multiple myeloma. Recent studies have demonstrated that certain therapeutic antibodies under development for the treatment of multiple myeloma are easily detected on serum IFE and can interfere with the detection and monitoring of M protein levels (McCudden et al., Clinical Chemistry, 56:12; 1897-1904 (2010); see also Genzen et al., British Journal of Haematology (2011) 155(1) 123-125). McCudden et al. observed that incubation of siltuximab (an anti-IL-6 antibody) with anti-drug antibodies shifted the drug electrophoretic pattern such that the therapeutic antibody siltuximab could be distinguished from endogenous M protein. Janssen has also recently published the development of a clinical assay to mitigate daratumumab interference with M protein in IFE using a similar approach, utilizing mouse anti-daratumumab antibodies ideally labeled with biotin or Alexa-fluor tags to shift the complex on IFE.Axel, et al., Development of a Clinical Assay to Mitigate Daratumumab, an IgG1k Monoclonal Antibody, Interference with Serum Immunofixation and Clinical Assessement of M-protein Response in Multiple Myeloma Poster Presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR), April 5-9, 2014, San Diego, California, USA; See also, Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunological Reviews, 270:95-112 (2016).
[0009] However, these approaches are not sufficient for all therapeutic antibodies. Novel mitigation strategies specific for each therapeutic antibody that avoid this potential interference with SPEP and IFE are needed to ensure the documentation of valid clinical responses that meet the International Myeloma Working Group (IMWG) criteria. Summary of the Invention
[0010] Applicants disclose herein an anti-idiotypic antibody against MOR202 which, when fused to human albumin, shifted the antibody in the IFE, thus mitigating any potential interference of MOR202 with M protein-based clinical evaluations.
[0011] Anti-idiotype antibody albumin fusions will be incorporated into the clinical development design of MOR202 to enhance clinical evaluation of M protein responses.
[0012] One aspect is an anti-idiotypic antibody against MOR202. In one aspect, the anti-idiotypic antibody is fused to human albumin. In an embodiment, the anti-idiotypic antibody is HCDR1 of the amino acid sequence YSFSNYWIS (SEQ ID NO: 18), HCDR2 of the amino acid sequence WMGIIDPASSKTRYSPSFQG (SEQ ID NO: 19); HCDR3 of amino acid sequence SRGAGMDY (SEQ ID NO:20) and a variable heavy chain comprising LCDR1 of the amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 21), LCDR2 of the amino acid sequence LLIYADNNRPS (SEQ ID NO: 22), LCDR3 of amino acid sequence GSYDESSNSM (SEQ ID NO:23) The variable light chain comprises
[0013] In one embodiment, the anti-idiotypic antibody is a human antibody.
[0014] In embodiments, the anti-idiotype antibody fusion has the amino acid sequence [ka] The heavy chain of
[0015] In embodiments, the anti-idiotype antibody fusion has the amino acid sequence [ka] The light chain of the antibody is
[0016] One embodiment is a method of evaluating a blood sample obtained from a patient undergoing treatment for multiple myeloma or other gammopathy, comprising: a) obtaining a blood sample from said patient; b) incubating the blood sample with an anti-idiotypic antibody; c) performing immunofixation electrophoresis (IFE); and d) Reporting the results of the IFE.
[0017] In an embodiment, the patient has undergone treatment with MOR202.
[0018] In an embodiment, the samples are assessed for total M protein levels.
[0019] One embodiment is a nucleic acid encoding an exemplary anti-idiotype antibody or an exemplary anti-idiotype antibody albumin fusion. [Brief description of the drawings]
[0020] [Figure 1] FIG. 1 shows the amino acid sequence of MOR202. [Figure 2A] FIG. 2A shows the amino acid sequence of MOR09292 (anti-idiotypic antibody to MOR202) human albumin fusion protein. [Figure 2B] FIG. 2B shows the amino acid sequence of MOR09292 (anti-idiotypic antibody to MOR202) human albumin fusion protein. [Diagram 3] FIG. 3 shows a typical standard pattern of protein distribution as determined by serum protein electrophoresis. [Figure 4] Figure 4 shows the serum protein electrophoretic distribution of a homogenous spike-like peak in a focal region of the gamma globulin band common to disorders known as monoclonal gammopathy, representing a single clone of plasma cells producing a homogenous M protein. [Diagram 5] Figure 5 shows an example of a gel after serum immunofixation electrophoresis of a healthy donor. Lane ELP = total protein staining; Lane G = anti-IgG staining; Lane A = anti-IgA staining; Lane M = anti-IgM staining; Lane K = anti-kappa staining; Lane L = anti-lambda staining. [Figure 6]Figure 6 shows serum immunofixation electrophoresis of samples from drug-naïve healthy donors (A and B) and drug-naïve MM patients (C and D). Samples were tested that were not spiked with MOR202 or spiked at various concentrations (Lane 1 = no MOR202 added; Lane 2 = MOR202 added at 200 μg / mL; Lane 3 = MOR202 added at 400 μg / mL; Lane 4 = MOR202 added at 800 μg / mL; Lane 5 = MOR202 added at 1200 μg / mL). The bands surrounded by dotted lines are visible only after MOR202 spiking and represent the respective molecules. The bands marked with arrows represent endogenous M protein. [Figure 7] Figure 7 shows serum immunofixation electrophoresis of MOR202 + / - MOR0929 IgG1 and MOR09292 IgM preincubation in saline. MOR202 at a constant concentration of 1200 μg / mL (A and B) or 560 μg / mL (C) in saline was preincubated with its idiotypic antibody MOR09292 in different formats and the prepared samples were analyzed by IFE. A)+B): MOR202 and MOR09292 IgG1 with anti-IgG staining (A) and anti-lambda staining (B) (Lane 1 = MOR202; Lane 2 = MOR09292 IgG1 2400 μg / mL; Lane 3 = MOR202 + MOR09292 IgG1 600 μg / mL; Lane 4 = MOR202 + MOR09292 IgG1 1200 μg / mL; Lane 5 = MOR202 + MOR09292 IgG1 2400 μg / mL). C): MOR202 and MOR09292 IgM with anti-IgG staining (lanes 2-4), anti-lambda staining (lanes 5-7), and anti-IgM staining (lanes 8-10) (lanes 2 / 5 / 8 = MOR202; lanes 3 / 6 / 9 = MOR09292 IgM 560 µg / mL; lanes 4 / 7 / 10 = MOR202 + MOR09292 IgM 560 µg / mL; lane 1 = human serum from a healthy donor stained for total protein to assess general background signaling in the serum sample). [Figure 8]FIG. 8 shows serum immunofixation electrophoresis of preincubation of MOR202+ / -MOR09292 human albumin fusion (MOR09292-hAlb) in saline and human serum. MOR202 was preincubated at various ratios with or without its idiotypic antibody MOR09292-hAlb at a constant concentration of 1200 μg / mL in saline (lanes 2-3) or serum (lanes 4-13) and samples were analyzed by IFE using anti-IgG staining (lanes 2-8) or anti-lambda staining (lanes 9-13). (Lane 2 = MOR202; lane 3 = MOR202 + MOR09292-hAlb 2400 μg / mL; lane 4 = MOR202; lane 5 = MOR202 + MOR09292-hAlb 1200 μg / mL; lane 6 = MOR202 + MOR09292-hAlb 1800 μg / mL; lane 7 = MOR202 + MOR09292-hAlb Lane 10 = MOR202+MOR09292-hAlb 1200 μg / mL; Lane 11 = MOR202+MOR09292-hAlb 1800 μg / mL; Lane 12 = MOR202+MOR09292-hAlb 2400 μg / mL; Lane 13 = MOR202+MOR09292-hAlb 3600 μg / mL; Lane 1 = human serum from a healthy donor stained for total protein to assess general background signaling). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] definition The term "anti-idiotype" describes a protein or peptide that binds to the variable region of an antibody. The anti-idiotype protein can be an antibody. For example, the antibody MOR09292 binds to the variable region of MOR202.
[0022] The term "antibody" includes antibody fragments. Antibodies include monoclonal antibodies of any isotype, such as IgG, IgM, IgA, IgD, and IgE. IgG antibodies consist of two identical heavy chains and two identical light chains, which are linked by disulfide bonds. The heavy and light chains of an antibody contain a constant region and a variable region. Each variable region contains three segments called "complementarity determining regions" ("CDRs") or "hypervariable regions", which are primarily responsible for binding to an epitope of an antigen. Counting sequentially from the N-terminus, they are called CDR1, CDR2, and CDR3. The more highly conserved parts of the variable region outside the CDRs are called "framework regions". "Antibody fragment" refers to Fv, scFv, dsFv, Fab, Fab'F(ab')2 fragments, or other fragments, which contain at least one variable heavy or variable light chain, respectively, and contain CDR and framework regions.
[0023] "CDR" is defined herein by Chothia et al., Kabat et al., or internal numbering conventions. See Chothia C, Lesk AM. (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol., 196(4):901-17, incorporated by reference in its entirety. See Kabat EA, Wu TT, Perry HM, Gottesman KS and Foeller C. (1991) Sequences of Proteins of Immunological Interest. 5th edit., NIH Publication no. 91-3242, US Dept. of Health and Human Services, Washington, DC, incorporated by reference in its entirety.
[0024] "VH" refers to the variable region of the immunoglobulin heavy chain of an antibody or antibody fragment. "VL" refers to the variable region of the immunoglobulin light chain of an antibody or antibody fragment.
[0025] "Fc region" means the constant region of an antibody, which in humans may be of IgG1, 2, 3, 4 subclass or other. The sequences of human Fc regions are available at IMGT, Human IGH C-REGIONs, http: / / www.imgt.org / ligmdb / (retrieved February 22, 2016).
[0026] As used herein, a "human antibody" or "human antibody fragment" includes antibodies and antibody fragments having variable regions in which both the framework and CDR regions are derived from sequences of human origin. Additionally, if the antibody contains a constant region, the constant region is also derived from such sequences.
[0027] "Specific" describes a protein that recognizes an antigen and is able to distinguish between such antigen and one or more reference antigens. This ability can be identified by standard ELISA assays. Typically, the determination of specificity is performed by using a set of about 3 to 5 unrelated antigens, e.g., milk powder, BSA, transferrin, etc., rather than a single reference antigen.
[0028] "Evaluating a blood sample" means evaluating the blood or the part of the blood sample that is most relevant to the method. Currently, immunofixation electrophoresis is done on the serum component of blood. However, in the future, if a different blood component is evaluated, the present invention is directed to a method of evaluating that blood component. Blood components include, for example, plasma, serum, cells such as red and white blood cells, and platelets. Plasma includes proteins such as globulins, and clotting factors, as well as salts, sugars, fats, hormones, and vitamins.
[0029] Gammopathy is a condition in which serum immunoglobulin levels are greatly increased, which can be classified as polyclonal (increased levels of all major immunoglobulin classes) or monoclonal (increased levels of a single homogeneous immunoglobulin).
[0030] Polyclonal gammopathy results from chronic stimulation of the immune system. It may therefore be caused by chronic pyoderma; chronic viral, bacterial, or fungal infections; granulomatous bacterial disease; abscesses; chronic parasitic infections; chronic rickettsial diseases, such as tropical canine pancytopenia; chronic immune disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and myositis; or by some neoplasias. In many cases, there is no obvious predisposing factor. In some animals, gammopathy may initially be monoclonal, due to the predominance of a single immunoglobulin class, usually IgG.
[0031] Monoclonal gammopathy is characterized by the production of large amounts of a single immunoglobulin protein. Monoclonal gammopathy may be benign (i.e., without an underlying disease) or, more commonly, associated with an immunoglobulin-secreting tumor. Tumors that secrete monoclonal antibodies originate from plasma cells (myelomas). Myelomas can secrete intact proteins of any immunoglobulin class, or subunits or fragments of immunoglobulins (light or heavy chains). Examples of monoclonal gammopathy include: Hodgkin's disease; variants of multiple myeloma, such as isolated plasmacytoma of bone, extramedullary plasmacytoma, plasma cell leukemia, and non-secretory myeloma, lymphoproliferative disorders, such as Waldenstrom's macroglobulinemia and lymphoma; heavy chain disease (gamma, alpha, mu); and amyloidosis.
[0032] The term "CD38" refers to the protein known as CD38, which has the following synonyms: ADP-ribosyl cyclase 1, cADPr hydrolase 1, cyclic ADP ribose hydrolase 1, T10.
[0033] Human CD38 has the following amino acid sequence: [ka]
[0034] The amino acid sequence of the anti-CD38 antibody "MOR202" is shown in Figure 1. "MOR202" and "MOR03087" are used synonymously to describe the antibody shown in Figure 1.
[0035] The DNA sequence encoding the MOR202 variable heavy domain is as follows: [ka]
[0036] The DNA sequence encoding the MOR202 variable light domain is as follows: [ka]
[0037] MOR202 is disclosed in WO 2007 / 042309, U.S. Patent Application No. 12 / 089,806, which are incorporated by reference in their entireties. In U.S. Patent Application No. 12 / 089,806, MOR202 is an antibody comprising a variable heavy chain corresponding to SEQ ID NO:21 and a variable light chain corresponding to SEQ ID NO:51, and the nucleic acid encoding MOR202 is the variable heavy chain SEQ ID NO:6 and the variable light chain SEQ ID NO:36.
[0038] MOR202 is currently being tested in a Phase 1 / 2a trial in patients with relapsed / refractory myeloma. The study is evaluating the safety and preliminary efficacy of MOR202 as monotherapy and in combination with pomalidomide and lenalidomide, and dexamethasone.
[0039] The antibody MOR09292 is an anti-idiotypic antibody to MOR202 and is encoded by the following nucleic acid sequence: VH: [ka] VL: [ka]
[0040] DNA encoding MOR09292-VH-CH1_HSA_6His (without leader sequence) (MOR09292-hAlb heavy chain): [ka]
[0041] DNA encoding MOR09292-VL-lambda (without leader sequence) (MOR09292-hAlb light chain): [ka]
[0042] Human albumin has the following amino acid sequence (including the signal sequence): [ka]
[0043] The International Myeloma Working Group (IMWG) Uniform Response Criteria for multiple myeloma are as follows: [Table 1A] [Table 1B] [Table 1C]
[0044] Electrophoresis is a method of separating proteins based on their biochemical properties. Serum is placed on a specific medium and an electric charge is added. The net charge (positive or negative) of the protein as well as its size and shape are commonly used to distinguish between various serum proteins.
[0045] Several subsets of serum protein electrophoresis are available, named based on the methods used to separate and differentiate the various serum components. In zone electrophoresis, for example, the various protein subtypes are placed in distinct physical locations on a gel made from agar, cellulose, or other plant materials. The proteins are stained and their concentrations are calculated electronically to provide graphical data regarding the absolute and relative amounts of the various proteins. Further separation of protein subtypes is achieved by immunofixation and / or staining with immunologically active agents resulting in immunofluorescence.
[0046] The pattern of serum protein electrophoresis results is determined by the fractionation of two major proteins: albumin and globulins. The major protein component of serum, albumin, is produced by the liver under normal physiological conditions. Globulins constitute a smaller fraction of the total serum protein content. The subsets of proteins and their relative amounts are most often the primary focus of serum protein electrophoresis interpretation.
[0047] The largest peak observed in serum protein electrophoresis, albumin, is located closest to the positive electrode. The next five components (globulins) are labeled alpha 1, alpha 2, beta 1, beta 2, and gamma. The peaks for these components appear closer to the negative electrode, with the gamma peak closest to the electrode.
[0048] FIG. 3 shows a typical standard pattern of protein distribution as determined by serum protein electrophoresis.
[0049] Albumin band represents the largest protein component of human serum. Albumin levels are reduced under conditions of less protein production by the liver or increased loss or degradation of said protein. Malnutrition, significant liver disease, renal loss (e.g., in nephrotic syndrome), hormone therapy, and pregnancy can cause low albumin levels. Burns can also result in low albumin levels. Albumin levels are increased, for example, in patients with relatively reduced serum water (e.g., dehydration).
[0050] Moving to the negative portion of the gel (i.e., the negative pole), the next peaks are associated with alpha 1 and alpha 2 components. The alpha 1 protein fraction is composed of alpha 1-antitrypsin, thyroid-binding globulin, and transcortin. Malignancy and acute inflammation (derived from acute phase reactants) can increase the alpha 1 protein band. Diminished alpha 1 protein bands can occur due to deficiency of alpha 1-antitrypsin or decreased production of globulin as a result of liver disease. Ceruloplasmin, alpha 2-macroglobulin, and haptoglobin contribute to the alpha 2 protein band. The alpha 2 component increases as an acute phase reactant.
[0051] The beta fraction has two peaks, labeled β1 and β2. Beta1 is mostly composed of transferrin, while beta2 contains beta-lipoproteins. IgA, IgM, and occasionally IgG can also be identified within the beta fraction, along with complement proteins.
[0052] Most of the clinical interest is focused on the gamma region of the serum protein spectrum because immunoglobulins migrate in this region. It should be noted that immunoglobulins can often be found throughout the electrophoretic spectrum. C-reactive protein (CRP) is located in the region between the beta and gamma components.
[0053] Many conditions can cause an expansion of the gamma region, but some disease states cause homogenous spike-like peaks in focal areas of the gamma globulin band (Figure 4).The so-called "monoclonal gammopathy" constitutes a group of disorders characterized by the proliferation of a single or very few clones of plasma cells each producing a homogenous M protein, e.g., MM.
[0054] Immunofixation electrophoresis (IFE) is a technique in which proteins can be fixed after electrophoresis by forming insoluble complexes with added monoclonal or polyclonal detection antibody reagents. It is carried out in four steps: 1) Separation of proteins by electrophoresis. 2) Immunofixation (immunoprecipitation) of electrophoresed proteins - the appropriate electrophoretic tracks are coated with individual antisera, which diffuse into the gel and precipitate the corresponding antigens, if present. The proteins in the reference tracks are fixed with a fixative. 3) Non-precipitated, soluble proteins are removed from the gel by blotting and washing. Precipitated antigen-antibody complexes are trapped within the gel matrix. 4) The precipitated proteins are visualized by staining (eg, acid violet staining).
[0055] To detect and identify suspected monoclonal components, the samples are electrophoresed simultaneously in several parallel tracks (see diagram). After electrophoresis, the ELP track serves as a reference (containing total protein fixation) to provide a complete electrophoretic pattern of the proteins of the serum sample. The remaining tracks allow characterization of the monoclonal components, usually from reaction with antisera against the heavy chains of human IgG, IgA, and IgM, and against free and bound kappa and lambda light chains, or from the lack of reaction. Other antisera (e.g. anti-IgD, etc.) are also possible. The immunofixed bands are then compared with the suspect bands in the reference pattern - the corresponding bands should have the same electrophoretic position.
[0056] Figure 5 shows an example of a gel after serum immunofixation electrophoresis. Serum samples from healthy donors were separated 6x in parallel by gel electrophoresis, but each lane was stained with a different reagent. After staining, uncomplexed proteins were removed by blotting and washing. Lane ELP = total protein staining; Lane G = anti-IgG staining; Lane A = anti-IgA staining; Lane M = anti-IgM staining; Lane K = anti-kappa staining; Lane L = anti-lambda staining. EXAMPLES
[0057] Materials and Methods IFE Immunofixation was performed using Sebia's semi-automated agarose gel electrophoresis systems Hydrasys and Hydrasys2, and using Sebia's Maxikit Hydragel 9IF. The kit is designed for the detection of immunoglobulins in human serum by immunofixation electrophoresis and contains all the necessary reagents and materials, i.e. agarose gel, buffered strips, diluent, acid violet stain, antisera (e.g., IgG, IgA, IgM, kappa and lambda), fixative solution, and applicators.
[0058] To evaluate the impact of MOR202 on M protein analysis, serum samples from healthy donors and MM patients were spiked with MOR202 at various concentrations and incubated at room temperature (RT) for at least 15 minutes. Samples spiked or not with MOR202 were then analyzed using IFE, staining gels with anti-IgG or anti-lambda antisera (both staining reagents capable of binding MOR202). In both stains, MOR202 was already detected at the lowest concentration tested at 200 μg / mL, suggesting IFE interference at or even below this drug serum level (FIG. 6).
[0059] To distinguish between MOR202-related assay signals in IFE and endogenous M protein spikes, a method was tested in which MOR202-containing samples were preincubated with a MOR202-specific anti-idiotypic antibody (MOR09292). The purpose of the method was to demonstrate that MOR202-related IFE assay signals could be run and compared with samples that were preincubated with or without MOR09292, so that MOR202-related assay signals could be clearly identified. To assess whether the migration distance was large enough to be detected, samples containing MOR202 in saline were prepared and preincubated with or without MOR09292. Anti-idiotypic antibodies were generated and tested in IgG1 and IgM antibody formats. Test samples were prepared with MOR202 at a fixed concentration of 1200 μg / mL and preincubated for 60 minutes without or with various concentrations of the two MOR09292 variants. Samples were then analyzed and IFE gels stained with anti-IgG or anti-lambda antisera. The results were that when test samples were pre-incubated with various forms of MOR09292, acceptable migration distances of MOR202 drug spikes suitable for clinical sample evaluation could not be observed (Figure 7). A surprising finding was that even increasing the size of the drug / antibody complex by approximately 3-fold (MOR09292-IgG) or 7-fold (MOR09292-IgM) compared to the drug antibody alone demonstrated that the change in molecular weight of the complex did not result in a reasonable shift in the assay signal (i.e., a change in migration pattern).
[0060] Based on these results, further variants of the idiotypic antibody were generated by genetically fusing the MOR09292-Fab fragment to human albumin (MOR09292-hAlb). The new variants increased the size of the drug-antibody complexes up to 2.6-fold compared to the drug-antibody alone. More importantly, the incorporation of human serum albumin lowered the overall net charge of the complexes. Sample preparation and testing were performed as previously described. As a result, a clear shift of the MOR202 / MOR09292-huAlb complexes could be observed when compared to the assay signal of MOR202 alone. See Figure 8.
[0061] A modified IFE assay using MOR09292-hAlb for sample pretreatment was incorporated into the clinical development of MOR202. The assay was therefore validated at a central laboratory responsible for M protein analysis and introduced into the testing strategy as the "Immunofixation Reflex Assay". To distinguish between MOR202-related and M protein-related signals, the IFE reflex assay was performed in addition to regular serum IFE and serum protein electrophoresis (SPE), for example, when the following two conditions were met: a) a reduction in serum M protein levels of at least ≧40% compared to M protein concentration pretreatment; and b) At least one of the remaining M protein spikes is characteristic of the drug antibody MOR202 (i.e., IgG / lambda positive staining in IFE).
[0062] A case study on the use and results of the IFE reflex assay within clinical study MOR202C101 Within the first clinical study (MOR202C101) of multiple myeloma patients treated with MOR202, an IFE reflex assay was performed on patient 19007 after a reduction of serum M protein levels of ≧86% was observed. For this patient, the identified M protein spike was described by IFE as IgG / lambda positive, the same molecular characteristic known for MOR202. SPE was performed to detect residual concentrations of 1 or 2 g / L of potential M protein on January 12, 2106 and February 19, 2016. The IFE reflex assay could demonstrate that this assay signal is exclusively caused by MOR202 interference, and therefore does not involve M protein (see summary laboratory results in Table 1). The results demonstrate how the newly established IFE reflex assay can clearly discriminate between M protein and therefore disease-related assay signals and MOR202 treatment-related assay signals. [Table 2]
[0063] Embodiment One embodiment is an anti-idiotype antibody fused to albumin. In one embodiment, the albumin is human albumin having the amino acid sequence of SEQ ID NO: 6. In one embodiment, the human albumin is a fragment of human albumin or a subsequence of human albumin.
[0064] In one embodiment, the albumin is a functional fragment of albumin. In another embodiment, the human albumin is a functional fragment of human albumin. In this context, the term "functional fragment" of albumin or human albumin refers to an albumin that is a fragment or variant of native albumin or human albumin, but is still functionally active, in the sense that it is still capable of fulfilling the physiological role of albumin.
[0065] One embodiment has a variable heavy domain comprising the amino acid sequence [ka] and A variable light chain domain comprising the amino acid sequence [ka] The antibody is an anti-idiotypic antibody that is specific for an antibody having the
[0066] One embodiment is a variable heavy domain comprising the amino acid sequence [ka] and A variable light chain domain comprising the amino acid sequence [ka] In one embodiment, the anti-idiotypic antibody is fused to albumin. In one embodiment, the albumin is human albumin having the amino acid sequence of SEQ ID NO: 6. In one embodiment, the human albumin is a fragment of human albumin or a subsequence of human albumin. In one embodiment, the human albumin is a functional fragment of human albumin or a subsequence of human albumin.
[0067] In embodiments, the anti-idiotypic antibody is HCDR1 of the amino acid sequence YSFSNYWIS (SEQ ID NO: 18), HCDR2 of the amino acid sequence WMGIIDPASSKTRYSPSFQG (SEQ ID NO: 19); HCDR3 of amino acid sequence SRGAGMDY (SEQ ID NO:20) and a variable heavy chain comprising LCDR1 of the amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 21), LCDR2 of the amino acid sequence LLIYADNNRPS (SEQ ID NO: 22), LCDR3 of amino acid sequence GSYDESSNSM (SEQ ID NO:23) The variable light chain comprises
[0068] In one embodiment, the anti-idiotypic antibody is a human antibody.
[0069] In embodiments, the anti-idiotypic antibody has a variable heavy chain of the following amino acid sequence: [ka] and Variable light chain of the following amino acid sequence: [ka] Includes.
[0070] In embodiments, the anti-idiotype antibody albumin fusion comprises the heavy chain amino acid sequence [ka] Includes.
[0071] In embodiments, the anti-idiotype antibody albumin fusion comprises the light chain amino acid sequence [ka] Includes.
[0072] One embodiment is a method of evaluating a blood sample obtained from a patient undergoing treatment for multiple myeloma or other gammopathy, comprising: e) obtaining a blood sample from said patient; f) incubating the blood sample with an anti-idiotypic antibody; g) performing immunofixation electrophoresis (IFE); and h) Reporting the results of the IFE.
[0073] In an embodiment of the method, the patient has the amino acid sequence [ka] and a variable heavy domain comprising the amino acid sequence [ka] The present inventors have experienced treatment with an antibody having a variable light chain domain comprising:
[0074] In one embodiment of the method, the anti-idiotypic antibody is fused to albumin. In one embodiment of the method, the albumin is human albumin having the amino acid sequence of SEQ ID NO: 6. In one embodiment of the method, the human albumin is a fragment of human albumin or a subsequence of human albumin.
[0075] The illustrated anti-idiotypic antibody MOR09292 is specific for MOR202. The anti-idiotypic antibody against MOR202, when fused to human albumin, shifts the antibody in IFE, thus mitigating any potential interference of MOR202 with M protein-based clinical evaluation. It is expected that fusions of other anti-idiotypic antibodies specific for other antibodies used in therapy in multiple myeloma or other gammopathies will have similar results. This means that other anti-idiotypic antibody albumin fusions will be useful for shifting the antibody in IFE, thus mitigating any potential interference of the antibody with M protein-based clinical evaluation.
[0076] In an embodiment of the method, the anti-idiotypic antibody is HCDR1 of the amino acid sequence YSFSNYWIS (SEQ ID NO: 18), HCDR2 of the amino acid sequence WMGIIDPASSKTRYSPSFQG (SEQ ID NO: 19); HCDR3 of amino acid sequence SRGAGMDY (SEQ ID NO:20) and a variable heavy chain comprising LCDR1 of the amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 21), LCDR2 of the amino acid sequence LLIYADNNRPS (SEQ ID NO: 22), LCDR3 of amino acid sequence GSYDESSNSM (SEQ ID NO:23) The variable light chain comprises
[0077] In an embodiment of the method, the anti-idiotypic antibody is a human antibody.
[0078] In an embodiment of the method, the anti-idiotypic antibody has the amino acid sequence [ka] and The amino acid sequence [ka] The variable light chain comprises
[0079] In an embodiment of the method, the anti-idiotype antibody albumin fusion has the heavy chain amino acid sequence: [ka] Includes.
[0080] In an embodiment of the method, the anti-idiotype antibody albumin fusion has the light chain amino acid sequence: [ka] Includes.
[0081] In an embodiment of the method, the sample is obtained from a patient undergoing treatment for multiple myeloma or other gammopathy. In a further embodiment, the gammopathy is a monoclonal gammopathy. In a further embodiment, the monoclonal gammopathy includes: Hodgkin's disease; variants of multiple myeloma, such as isolated plasmacytoma of bone, extramedullary plasmacytoma, plasma cell leukemia, and non-secretory myeloma, lymphoproliferative disorders, such as Waldenstrom's macroglobulinemia and lymphoma; heavy chain diseases (gamma, alpha, mu); and amyloidosis.
[0082] In an embodiment of the method, the sample is assessed for total M protein levels.
[0083] One aspect is a nucleic acid encoding an exemplary anti-idiotype antibody or anti-idiotype antibody albumin fusion. In one embodiment, the anti-idiotype antibody is MOR09292. In one embodiment, the anti-idiotype antibody is encoded by a nucleic acid sequence that encodes the amino acid sequence shown in Figures 2A-2B.
[0084] In one embodiment, the anti-idiotypic antibody is encoded by the nucleic acid sequences of SEQ ID NO:26 (VH) and SEQ ID NO:27 (VL).
Claims
1. A nucleic acid encoding the chains of a monoclonal anti-idiotypic antibody specific for an anti-CD38 antibody, said anti-CD38 antibody comprising a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:7, and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:8; The monoclonal anti-idiotype antibody is a nucleic acid comprising a VH chain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 18, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 19, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 20, and a VL chain comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 21, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 22, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
23.
2. The nucleic acid of claim 1 , wherein the monoclonal anti-idiotypic antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 16 and a variable light chain comprising the amino acid sequence of SEQ ID NO:
17.
3. The nucleic acid of claim 1 , wherein the monoclonal anti-idiotypic antibody is an IgG.
4. The nucleic acid of claim 1 , wherein the monoclonal anti-idiotypic antibody is IgM.
5. The nucleic acid of claim 1 , which encodes VH and comprises the sequence of SEQ ID NO:
4.
6. The nucleic acid according to claim 5, which consists of the sequence of SEQ ID NO:
4.
7. The nucleic acid according to claim 5, which consists of the sequence of SEQ ID NO:
26.
8. The nucleic acid of claim 1 , which encodes VL and comprises the sequence of SEQ ID NO:
5.
9. The nucleic acid according to claim 8, which consists of the sequence of SEQ ID NO:
5.
10. A nucleic acid according to claim 8, consisting of the sequence of SEQ ID NO:
27.
11. The nucleic acid of claim 5, further comprising a nucleic acid encoding VL and comprising the sequence of SEQ ID NO:
5.
12. 12. The nucleic acid of claim 11, wherein the nucleic acid encoding VH consists of the sequence of SEQ ID NO: 4 and the nucleic acid encoding VL consists of the sequence of SEQ ID NO:
5.
13. 12. The nucleic acid of claim 11, wherein the nucleic acid encoding VH consists of the sequence of SEQ ID NO: 26 and the nucleic acid encoding VL consists of the sequence of SEQ ID NO: 27.
Citation Information
Patent Citations
Human anti-idiotypic antibody fragments that mimic her-2 / neu
JP2008504221A
Antibodies against cd38 for treatment of multiple myeloma
JP2008533977A
Anti-CD19 antibody and use in oncology
JP2012140446A
Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
JP2013542191A
Manufacturing, characterization, and applications of anti-HER3 antibodies
JP2014504850A
